Pro Chart

Twist Bioscience Corporat...

NasdaqGS: TWST · Real-Time Price · USD
123.63
+0.51 (0.41%)
At close: Aug 12, 2026, 11:30 AM

Twist Bioscience Corporation (TWST) Stock Price, Analysis & Data

0.41%
Bid88.2
Market Cap7.75B
Revenue (ttm)431.8M
Net Income (ttm)-136.72M
Beta2.16
EPS (ttm)-2.23
PE Ratio (ttm)n/a
Forward PE-195.21
P/B (ttm)17.38
P/S (ttm)17.95
Earnings DateNov 16, 2026
Ask156.81
Volume372,671
Avg. Volume (20D)1,785,385
Open124.00
Previous Close123.12
Day's Range120.94 - 124.00
52-Week Range23.30 - 125.66
AnalystBuy
Price Target115 (-6.98%)
Dividendsn/a
Ex-Dividend Daten/a

About TWST

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mu...

Sector Healthcare
IPO Date Oct 31, 2018
Employees 979
Stock Exchange NasdaqGS
Ticker Symbol TWST
Full Company Profile

Financial Performance

In 2025, Twist Bioscience's revenue was 376.57M, an increase of 20.32% compared to the previous year's 312.97M. Earnings were -77.67M, a decrease of -62.79%.

Financial Statements

Analyst Forecast

According to 10 analyst ratings, the average rating for TWST stock is "Buy". The 12-month stock price forecast is 115, which is downside of 6.98% from the latest price.

Stock Forecasts

Earnings Surprise

Twist Bioscience has released their quarterly earnings on Aug 3, 2026:
  • Revenue of $118.38M misses estimates by $0, with 23.24% YoY growth.
  • EPS of -0.56 misses estimates by -0.38, with -19.15% YoY decline.
  • Twist Bioscience Corporation is scheduled to release its earnings on Nov 16, 2026, before market opens.
    Analysts project revenue of ... Upgrade